E-LIB Suche - Ergebnisse für: Baiocchi, R.

1

Epigenetic insights into Epstein-Barr virus-associated lymp..:

Feleke, S.T. ; Zealiyas, K. ; Abebe, T....
Clinica Chimica Acta. 558 (2024) - p. 118239 , 2024

Link: https://doi.org/10.1016/..

2

DARATUMUMAB AND EPOCH FOR HIV+/‐ PLASMABLASTIC LYMPHOMA: A ..:

Noy, A. ; Barta, S. K. ; Tan, C. R....
Hematological Oncology. 41 (2023) S2 - p. 710-710 , 2023

Link: https://doi.org/10.1002/..

3

49O Clinical experience of tabelecleucel in Epistein-Barr v..:

Baiocchi, R. ; Choquet, S. ; Ghosh, M....
Immuno-Oncology and Technology. 20 (2023) - p. 100522 , 2023

Link: https://doi.org/10.1016/..

4

Combination of the PD‐1 inhibitor Nivolumab and Immunomodul..:

Bond, D. A. ; Wei, L. ; Yildiz, V....
Hematological Oncology. 41 (2023) S2 - p. 597-598 , 2023

Link: https://doi.org/10.1002/..

5

P1250: EU-SOX11CCND1: A NOVEL IMMUNOCOMPETENT MURINE MODEL ..:

Brown, F. ; Sloan, S. ; Helmig-Mason, J....
HemaSphere. 6 (2022) - p. 1135-1136 , 2022

Link: https://doi.org/10.1097/..

6

P1244: ROLE OF SELECT T HELPER CELL MONONUCLEAR CELL SUBSET..:

Ahmed, E. H. ; Lustberg, M. ; Hale, C....
HemaSphere. 6 (2022) - p. 1129-1130 , 2022

Link: https://doi.org/10.1097/..

7

A SINGLE‐CENTER RETROSPECTIVE ANALYSIS OF THE TOXICITY OF H..:

Fleming, M ; Huang, Y ; Dotson, E...
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

8

PRMT5 INHIBITION RESTARTS A PRO‐APOPTOTIC PROGRAM AND CREAT..:

Brown, F ; Hwang, I ; Sloan, S...
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

9

A PHASE 1B/2 STUDY OF ORAL NANATINOSTAT (N) AND VALGANCICLO..:

Porcu, P. ; Haverkos, B. ; Brem, E....
Hematological Oncology. 37 (2019) S2 - p. 335-337 , 2019

Link: https://doi.org/10.1002/..

10

PHASE I DOSE‐ESCALATION STUDY OF VENETOCLAX PLUS BEAM FOLLO..:

Maakaron, J. ; Zhao, Q. ; Puto, M....
Hematological Oncology. 37 (2019) S2 - p. 528-529 , 2019

Link: https://doi.org/10.1002/..

11

CLINICAL OUTCOMES OF PATIENTS WITH T‐CELL LARGE GRANULAR LY..:

Brammer, J.E. ; Braunstein, Z. ; Mishra, A....
Hematological Oncology. 37 (2019) S2 - p. 481-482 , 2019

Link: https://doi.org/10.1002/..

12

CLINICAL OUTCOMES IN PATIENTS WITH EPSTEIN‐BARR VIRUS (EBV)..:

Brammer, J.E. ; Shindiapina, P. ; Freud, A....
Hematological Oncology. 37 (2019) S2 - p. 476-477 , 2019

Link: https://doi.org/10.1002/..

13

A PHASE II TRIAL OF BRENTUXIMAB VEDOTIN (BV) AND LENALIDOMI..:

William, B.M. ; Abbasi, A. ; Huang, Y....
Hematological Oncology. 37 (2019) S2 - p. 471-472 , 2019

Link: https://doi.org/10.1002/..

14

A phase 1 trial of Vorinostat in combination with concurren..:

Teknos, Theodoros N. ; Grecula, J. ; Agrawal, A....
Investigational New Drugs. 37 (2018) 4 - p. 702-710 , 2018

Link: https://doi.org/10.1007/..

15

PRMT5–PTEN molecular pathway regulates senescence and self-..:

Banasavadi-Siddegowda, Y K ; Russell, L ; Frair, E...
Oncogene. 36 (2016) 2 - p. 263-274 , 2016

Link: https://doi.org/10.1038/..